Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedemaAsad Farooq Durrani, Bita Momenaei, Taku Wakabayashi, Sudheshna Vemula, Saagar A Pandit, Jason Hsu, Allen C Ho, Marc J Spirn, Michael A Klufas, Sunir J Garg, James F Vander, Carl D Regillo, Allen Chiang, Ajay E Kuriyan, Yoshihiro Yonekawa
12 February 2024
Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumabRobert B Bhisitkul, Peter A Campochiaro, Steven Blotner, Carlos Quezada-Ruiz, Mimi Liu, Zdenka Haskova
30 January 2024
Intravitreal panitumumab and myopic macular degenerationMukharram M Bikbov, Gyulli M Kazakbaeva, Frank G Holz, Songhomitra Panda-Jonas, Leisan I Gilemzianova, Dinar A Khakimov, Jost B Jonas
10 July 2023
Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trialTimothy L Jackson, Cristina Soare, Caroline Petrarca, Andrew Simpson, James E Neffendorf, Robert Petrarca, Katherine Alyson Muldrew, Tunde Peto, Usha Chakravarthy, Luke Membrey, Richard Haynes, Mark Costen, David H W Steel, Riti Desai, Fiona BishopSee the full list of authors
25 February 2022
Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! RegistryAdrian Robert Hunt, Vuong Nguyen, Jennifer J Arnold, Ian L McAllister, Hemal Mehta, Alessandro Invernizzi, Theodorus Ponsioen, Pierre-Henry Gabrielle, Louise O'Toole, Pavol Kusenda, Socorro Alforja, Daniel Barthelmes, Mark C Gillies
25 January 2022
OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based studySimon KH Szeto, Vivian W. K. Hui, Fang Yao Tang, Dawei Yang, Zi han Sun, Shaheeda Mohamed, Carmen K M Chan, Timothy Y Y Lai, Carol Cheung
8 November 2021
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomesNeil M Bressler, Miroslav Veith, Jan Hamouz, Jan Ernest, Dominik Zalewski, Jan Studnička, Attila Vajas, András Papp, Gabor Vogt, James Luu, Veronika Matuskova, Young Hee Yoon, Tamás Pregun, Taehyung Kim, Donghoon ShinSee the full list of authors
16 October 2021
Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapyMengyuan Fang, Karntida Chanwimol, Jyotsna Maram, Ghazala A Datoo O'Keefe, Charles C Wykoff, David Sarraf, A’sha Brown, Shaun Ian Retief Lampen, Brenda Zhou, Alexander M Rusakevich, SriniVas Sadda
24 September 2021
Contrast sensitivity and quality of life following intravitreal ranibizumab injection for central retinal vein occlusionTomoya Murakami, Fumiki Okamoto, Yoshimi Sugiura, Shohei Morikawa, Yoshifumi Okamoto, Takahiro Hiraoka, Tetsuro Oshika
27 August 2021
Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX studySamantha Fraser-Bell, Hyong Kwon Kang, Paul Mitchell, Jennifer J Arnold, Jodi Tainton, Susan Simonyi
25 August 2021
